Literature DB >> 25500146

Mortality within 30 days following systemic anti-cancer therapy, a review of all cases over a 4 year period in a tertiary cancer centre.

L Khoja1, A McGurk1, C O'Hara1, S Chow1, J Hasan2.   

Abstract

BACKGROUND: The national confidential enquiry into patient outcomes and death (NCEPOD) set important benchmarks in assessing the quality of care received by patients dying within 30 days of systemic anticancer therapy (SACT). Monthly morbidity and mortality audits conducted to recommendations in the NCEPOD were commenced at the Christie NHS Foundation Trust in 2009, specifically to assess and improve patient outcomes.
METHODS: We evaluated the outcomes of patients who died within 30 days of SACT over a 4 year period 2009-2013. We collated audit findings to determine the number of treatment related deaths, clinical characteristics of patients, causes of death and quality of care received. We examined the benefit of the audit in decreasing 30 day mortality during the 4 years and considered factors that may be associated with an increased risk of SACT related death.
RESULTS: A total of 31,183 patients were treated at the Christie from 2009 to 2013. Of these 4% died within 30 days of SACT. Death was treatment related in 11%. The decision to treat with SACT was appropriate in 87% of but there was room for improvement in care in 24%. Mortality decreased over the 4 years. Possible factors associated with 30 day mortality post SACT included performance status ⩾2, presence of comorbidities, treatment type and treatment setting.
CONCLUSIONS: We demonstrated that our audit process is feasible and robust. Further areas of research to determine predictive scores for patient treatment selection and improve outcomes were highlighted and are ongoing.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  30Day SACT mortality; Clinical governance; NCEPOD; Oncology

Mesh:

Substances:

Year:  2014        PMID: 25500146     DOI: 10.1016/j.ejca.2014.11.011

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  The Incidence of Respiratory Infections and Risk Factors Among Cancer Patients Undergoing Chemotherapy at a Tertiary Care Hospital in Western Saudi Arabia.

Authors:  Abdulaziz F Alharbi; Mohammed A Bomonther; Saif AlJuaed; Suliman R Bakedo; Abdullah A Awadh; Fayssal Farahat
Journal:  Cureus       Date:  2022-08-24

2.  Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic.

Authors: 
Journal:  BMJ Glob Health       Date:  2022-10

3.  Thirty-Day Mortality After Curative and Palliative Anti-Cancer Treatment: Data Interpretation and Lessons for Clinical Implementation.

Authors:  Emad Tashkandi; Bassam Basulaiman; Waleed Alghareeb; Faris Hamadi; Anas Alghamdi; Faez Albabakri; Redhwan Alshabi; Mohammad Jaffal; Abdulrahman Albaradie; Ruqayya Azher
Journal:  Cancer Manag Res       Date:  2020-12-01       Impact factor: 3.989

4.  30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.

Authors:  Michael Wallington; Emma B Saxon; Martine Bomb; Rebecca Smittenaar; Matthew Wickenden; Sean McPhail; Jem Rashbass; David Chao; John Dewar; Denis Talbot; Michael Peake; Timothy Perren; Charles Wilson; David Dodwell
Journal:  Lancet Oncol       Date:  2016-08-30       Impact factor: 41.316

5.  Development of an intervention to support patients and clinicians with advanced lung cancer when considering systematic anticancer therapy: protocol for the PACT study.

Authors:  Despina Anagnostou; Stephanie Sivell; Simon Noble; Jason Lester; Anthony Byrne; Catherine Sampson; Mirella Longo; Annmarie Nelson
Journal:  BMJ Open       Date:  2017-07-12       Impact factor: 2.692

6.  Improving the safety of chemotherapy prescribing in oncology through the introduction of an assessment proforma.

Authors:  Paula Scullin; Olivia Devlin; Caroline Forde
Journal:  BMJ Qual Improv Rep       Date:  2017-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.